Literature DB >> 21279548

Diagnosis and treatment of primary aldosteronism.

Paolo Mulatero1, Silvia Monticone, Franco Veglio.   

Abstract

Primary aldosteronism is the most common form of secondary hypertension. The detection of primary aldosteronism is of particular importance, not only because it provides an opportunity for a targeted treatment (surgical for APA and medical with mineralocorticoid receptor antagonists for BAH), but also because it has been extensively demonstrated that patients affected by PA are more prone to cardiovascular events and target organ damage than essential hypertensives. According to the Endocrine Society Guidelines diagnosis of PA is made following a rigorous flow-chart comprising screening, confirmation/exclusion testing and subtype diagnosis. In the present review we describe briefly the published diagnostic strategies of the Guidelines, highlighting new evidence that has become recently available and discuss issues that still need to be addressed by future research.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21279548     DOI: 10.1007/s11154-011-9156-6

Source DB:  PubMed          Journal:  Rev Endocr Metab Disord        ISSN: 1389-9155            Impact factor:   6.514


  65 in total

1.  Hyperaldosteronism among black and white subjects with resistant hypertension.

Authors:  David A Calhoun; Mari K Nishizaka; Mohammad A Zaman; Roopal B Thakkar; Paula Weissmann
Journal:  Hypertension       Date:  2002-12       Impact factor: 10.190

2.  A new form of hereditary primary aldosteronism: familial hyperaldosteronism type III.

Authors:  Paolo Mulatero
Journal:  J Clin Endocrinol Metab       Date:  2008-08       Impact factor: 5.958

3.  Steroidogenesis in aldosterone-producing adenoma revisited by transcriptome analysis.

Authors:  Guillaume Assié; Colette Auzan; Jean-Marie Gasc; Erno Baviera; André Balaton; Jean-Marc Elalouf; Xavier Jeunemaitre; Pierre-François Plouin; Pierre Corvol; Eric Clauser
Journal:  J Clin Endocrinol Metab       Date:  2005-10-04       Impact factor: 5.958

4.  Role for adrenal venous sampling in primary aldosteronism.

Authors:  William F Young; Anthony W Stanson; Geoffrey B Thompson; Clive S Grant; David R Farley; Jon A van Heerden
Journal:  Surgery       Date:  2004-12       Impact factor: 3.982

5.  Effect of age on response of secondary hypertension to specific treatment.

Authors:  D H Streeten; G H Anderson; S Wagner
Journal:  Am J Hypertens       Date:  1990-05       Impact factor: 2.689

6.  Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents.

Authors:  Paolo Mulatero; Michael Stowasser; Keh-Chuan Loh; Carlos E Fardella; Richard D Gordon; Lorena Mosso; Celso E Gomez-Sanchez; Franco Veglio; William F Young
Journal:  J Clin Endocrinol Metab       Date:  2004-03       Impact factor: 5.958

Review 7.  Adrenal causes of hypertension: pheochromocytoma and primary aldosteronism.

Authors:  William F Young
Journal:  Rev Endocr Metab Disord       Date:  2007-12       Impact factor: 6.514

8.  Plasma Renin test-guided drug treatment algorithm for correcting patients with treated but uncontrolled hypertension: a randomized controlled trial.

Authors:  Brent M Egan; Jan N Basile; Shakaib U Rehman; Phillip B Davis; Curt H Grob; Jessica Flynn Riehle; Christine A Walters; Daniel T Lackland; Carmen Merali; Jean E Sealey; John H Laragh
Journal:  Am J Hypertens       Date:  2009-04-16       Impact factor: 2.689

9.  Heterogeneity of aldosterone-producing adenomas revealed by a whole transcriptome analysis.

Authors:  Livia Lenzini; Teresa M Seccia; Enrico Aldighieri; Anna S Belloni; Paolo Bernante; Luisa Giuliani; Gastone G Nussdorfer; Achille C Pessina; Gian Paolo Rossi
Journal:  Hypertension       Date:  2007-10-15       Impact factor: 10.190

10.  Adrenal venous sampling in primary aldosteronism: a low dilution of adrenal venous blood is crucial for a correct interpretation of the results.

Authors:  Jiri Ceral; Miroslav Solar; Antonin Krajina; Marek Ballon; Petr Suba; Jan Cap
Journal:  Eur J Endocrinol       Date:  2009-07-15       Impact factor: 6.664

View more
  6 in total

1.  Evolution of computed tomography-detectable adrenal nodules in patients with bilateral primary aldosteronism.

Authors:  Paolo Mulatero; Jacopo Burrello; Barbara Lucatello; Gilberta Giacchetti; Marialberta Battocchio; Francesco Fallo
Journal:  Endocrine       Date:  2015-12-08       Impact factor: 3.633

2.  Outcome of surgical treatment of primary aldosteronism.

Authors:  Marilisa Citton; Giovanni Viel; Gian Paolo Rossi; Franco Mantero; Donato Nitti; Maurizio Iacobone
Journal:  Langenbecks Arch Surg       Date:  2015-01-08       Impact factor: 3.445

3.  Ambulatory Blood Pressure Monitoring-Derived Short-Term Blood Pressure Variability in Primary Aldosteronism.

Authors:  Andrea Grillo; Stella Bernardi; Andrea Rebellato; Bruno Fabris; Moreno Bardelli; Jacopo Burrello; Franco Rabbia; Franco Veglio; Francesco Fallo; Renzo Carretta
Journal:  J Clin Hypertens (Greenwich)       Date:  2015-04-16       Impact factor: 3.738

4.  Unadjusted Plasma Renin Activity as a "First-Look" Test to Decide Upon Further Investigations for Primary Aldosteronism.

Authors:  Peter Rye; Alex Chin; Janice Pasieka; Benny So; Adrian Harvey; Gregory Kline
Journal:  J Clin Hypertens (Greenwich)       Date:  2015-03-10       Impact factor: 3.738

Review 5.  Cerebro-Cardiovascular Risk, Target Organ Damage, and Treatment Outcomes in Primary Aldosteronism.

Authors:  Xiao Lin; Muhammad Hasnain Ehsan Ullah; Xiong Wu; Feng Xu; Su-Kang Shan; Li-Min Lei; Ling-Qing Yuan; Jun Liu
Journal:  Front Cardiovasc Med       Date:  2022-02-02

6.  Comprehensive re-sequencing of adrenal aldosterone producing lesions reveal three somatic mutations near the KCNJ5 potassium channel selectivity filter.

Authors:  Tobias Åkerström; Joakim Crona; Alberto Delgado Verdugo; Lee F Starker; Kenko Cupisti; Holger S Willenberg; Wolfram T Knoefel; Wolfgang Saeger; Alfred Feller; Julian Ip; Patsy Soon; Martin Anlauf; Pier F Alesina; Kurt W Schmid; Myriam Decaussin; Pierre Levillain; Bo Wängberg; Jean-Louis Peix; Bruce Robinson; Jan Zedenius; Martin Bäckdahl; Stefano Caramuta; K Alexander Iwen; Johan Botling; Peter Stålberg; Jean-Louis Kraimps; Henning Dralle; Per Hellman; Stan Sidhu; Gunnar Westin; Hendrik Lehnert; Martin K Walz; Göran Åkerström; Tobias Carling; Murim Choi; Richard P Lifton; Peyman Björklund
Journal:  PLoS One       Date:  2012-07-27       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.